March 13th 2024
Higher sensitivity for CRC and advanced precancerous lesions, but lower specificity for advanced neoplasia, was seen with a next-generation stool DNA test vs a fecal immunochemical test.
A CAR T-cell therapy directed toward 2 brain tumor–associated proteins displayed preliminary activity in recurrent glioblastoma.
Elisabeth I. Heath, MD, FACP, discusses what makes NECTIN-4 an attractive target in drug development and the significance of the EV-302/KEYNOTE-A39 trial findings.
March 12th 2024
The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome.
Andrea Porpiglia, MD, MSc, FACS, and Sanjay Reddy, MD, FACS describe what makes the Complex General Surgical Oncology Fellowship at Fox Chase unique.
March 7th 2024
Belantamab mafodotin plus pomalidomide and dexamethasone extended PFS in relapsed/refractory multiple myeloma.
Patients with upper tract urothelial cancer who received adjuvant chemotherapy after nephroureterectomy experienced extended DFS vs those who received surveillance.
March 6th 2024
R. Lor Randall, MD, FACS, discusses the top takeaways from the inaugural 2024 Birmingham Orthopedic Oncology Meeting.
March 5th 2024
David L. Porter, MD, discusses the decision by the FDA to call for a boxed warning for secondary malignancies on all approved CAR T-cell agents.
March 4th 2024
Rahul Banerjee, MD FACP, discusses the FDA’s decision to add a class-wide boxed warning for secondary malignancies on all approved CAR T-cell therapies.
February 29th 2024
SNB-101, a novel polymer nanoparticle agent, has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.
February 27th 2024
The biologics license application for first-line tislelizumab plus chemotherapy for gastric/gastroesophageal junction cancer has been accepted by the FDA.
February 22nd 2024
The FDA has granted IO-202 an orphan drug designation for patients with chronic myelomonocytic leukemia.
February 20th 2024
The sBLA for pembrolizumab plus chemotherapy in endometrial cancer has been granted priority review by the FDA.
Lurbinectedin demonstrated greater activity and a superior safety profile vs topotecan in a subset of small cell lung cancer.
February 19th 2024
The European Medicines Agency has granted orphan drug designation to UV1 in patients with mesothelioma.
February 16th 2024
The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of patients with soft tissue sarcoma.
February 14th 2024
The BLA seeking the approval of denileukin diftitox in patients with relapsed/refractory cutaneous T-cell lymphoma was resubmitted to the FDA.
The ongoing Flamingo-01 trial continues to investigate GLSI-100 in HER2/neu-positive breast cancer following various holds.
February 13th 2024
John Shen, MD, discusses the phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant prostate cancer.